PathoGenetix, which develops an automated system for rapid bacterial identification, has raised A $10m Series C round from existing investors Ascension Health Ventures, Excel Venture Management and HealthCare Ventures.
The company will use the Series C capital to further develop the first commercial system using the Genome Sequence Scanning (GSS) technology, the RESOLUTION Microbial Genotyping System.
GSS confirms and identifies microbial DNA in either complex mixtures or isolates, and provides actionable information in five hours.
Ascension Health Ventures managing director Tara Butler said, “We are excited about the potential for the GSS technology in a range of industrial, research and clinical applications.
“PathoGenetix product development and research continue to demonstrate clear benefits for use in the food industry. We also believe the technology has significant potential in research and clinical applications such as microbiome analyses and genome mapping.”
Other companies backed by Ascension Health Ventures include business intelligence technology provider Quantros, which secured a growth investment from the firm in August.
Copyright © 2012 AltAssets